UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on NxStage Medical
In a report published Friday, Jefferies & Company reiterated its Buy rating on NxStage Medical (NASDAQ: NXTM), but lowered its price target from $21.00 to $16.00.
Jefferies noted, “NXTM posted a decent 3Q. Overall HHD grew 17% but US HHD growth again decelerated (+12%) and will remain in check under the current reimbursement environment. The company outlined an increasing number of pipeline opportunities and while achieving increased reimbursement will take time, the substantial long-term HHD opportunity supports our Buy rating.”
NxStage Medical closed on Thursday at $10.61.
Latest Ratings for NXTM
|Sep 2014||Canaccord Genuity||Maintains||Buy|
|Mar 2014||Wells Fargo||Downgrades||Market Perform||Underperform|
|Jul 2013||Lazard Capital Markets||Downgrades||Buy||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.